Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03901469
Recruitment Status : Active, not recruiting
First Posted : April 3, 2019
Last Update Posted : July 13, 2021
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Zenith Epigenetics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : January 2022